Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. Estimates – LS:A41DXH
TradingView · 23 Oct 2026
Acurx publishes study on microbiome effects of antibiotic class By Investing.com
Investing.com Nigeria · 21 Oct 2026
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
TradingView · 21 Oct 2026
Acurx (ACXP) Stock Screener: -5.98% Decline on Elevated Volume 2026-10-16 - Large Cap Trends
https://www.siam.in/ · 16 Oct 2026
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
The Batesville Daily Guard · 05 Oct 2026
Acurx starts Phase 2 PATHFINDER trial for ibeza...
Pluang · 29 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.